Tumour burden and efficacy of immune-checkpoint inhibitors-Reference-Cited by-同舟云学术

Tumour burden and efficacy of immune-checkpoint inhibitors

Published:2021-10-12 Issue:2 Volume:19 Page:75-90
ISSN:1759-4774
Container-title:Nature Reviews Clinical Oncology
language:en
Short-container-title:Nat Rev Clin Oncol

Author:

Dall’Olio Filippo G.,Marabelle Aurélien^ORCID,Caramella Caroline,Garcia Camilo^ORCID,Aldea Mihaela,Chaput Nathalie,Robert Caroline^ORCID,Besse Benjamin

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

https://www.nature.com/articles/s41571-021-00564-3.pdf

Reference161 articles.

1. Ferrara, R. et al. Hyperprogressive disease in patients with advanced non–small cell lung cancer treated with PD-1/PD-L1 inhibitors or with single-agent chemotherapy. JAMA Oncol. 4, 1543–1552 (2018).

2. Kim, C. G. et al. Hyperprogressive disease during PD-1/PD-L1 blockade in patients with non-small-cell lung cancer. Ann. Oncol. 30, 1104–1113 (2019).

3. Ott, P. A. et al. T-cell–inflamed gene-expression profile, programmed death ligand 1 expression, and tumor mutational burden predict efficacy in patients treated with pembrolizumab across 20 cancers: KEYNOTE-028. J. Clin. Oncol. 37, 318–327 (2019).

4. Le, D. T. et al. PD-1 blockade in tumors with mismatch-repair deficiency. N. Engl. J. Med. 372, 2509–2520 (2015).

5. Overman, M. J. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 18, 1182–1191 (2017).

Cited by 167 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Microdroplet-enhanced chip platform for high-throughput immunotherapy marker screening from extracellular vesicle RNAs and membrane proteins;Biosensors and Bioelectronics;2025-01

2. Multi-omics landscape of Interferon-stimulated gene OASL reveals a potential biomarker in pan-cancer: from prognosis to tumor microenvironment;Frontiers in Immunology;2024-09-02

3. Exercise therapy: Anti-tumor and improving chemotherapy efficacy;Journal of Holistic Integrative Pharmacy;2024-09

4. Tislelizumab synergizes with surgery to augment the survival benefit in stage II-III non-small cell lung cancer;Discover Oncology;2024-08-31

5. Nanomedicine-based cancer immunotherapy: a bibliometric analysis of research progress and prospects;Frontiers in Immunology;2024-08-23